Solid Financial Statements From 2010 to 2025

SLDB Stock  USD 3.32  0.01  0.30%   
Solid Biosciences financial statements provide useful quarterly and yearly information to potential Solid Biosciences LLC investors about the company's current and past financial position, as well as its overall management performance and changes in financial position over time. Historical trend examination of various income statement and balance sheet accounts found on Solid Biosciences financial statements helps investors assess Solid Biosciences' valuation, profitability, and current liquidity needs. Key fundamental drivers impacting Solid Biosciences' valuation are summarized below:
Gross Profit
-76.6 M
Market Capitalization
132.6 M
Enterprise Value Revenue
1.1559
Earnings Share
(3.04)
Quarterly Revenue Growth
(1.00)
We have found one hundred twenty available fundamental trend indicators for Solid Biosciences LLC, which can be analyzed and compared to other ratios and to its competition. All investors should make sure to double-check all of Solid Biosciences LLC current market performance against the performance between 2010 and 2025 to make sure the company can sustain itself down the road. As of January 31, 2025, Market Cap is expected to decline to about 50 M. The current year's Enterprise Value is expected to grow to about (88.5 M)

Solid Biosciences Total Revenue

8.09 Million

Check Solid Biosciences financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Solid Biosciences' main balance sheet or income statement drivers, such as Interest Income of 8.5 M, Interest Expense of 24.7 M or Selling General Administrative of 20.8 M, as well as many indicators such as Price To Sales Ratio of 10.66, Dividend Yield of 0.0 or PTB Ratio of 0.91. Solid financial statements analysis is a perfect complement when working with Solid Biosciences Valuation or Volatility modules.
  
Check out the analysis of Solid Biosciences Correlation against competitors.

Solid Biosciences Balance Sheet

Current ValueLast YearHistorical Average 10 Year Trend
Total Assets152.1 M189.7 M116.5 M
Slightly volatile
Other Current Liabilities7.7 M11.7 M9.3 M
Slightly volatile
Total Current Liabilities18.1 M16.7 M15.8 M
Slightly volatile
Accounts PayableM2.3 M2.6 M
Slightly volatile
Cash92.2 M85.1 M67.1 M
Slightly volatile
Cash And Short Term Investments130.5 M142.2 M101.1 M
Slightly volatile
Common Stock Total Equity17.1 K18 K4.2 M
Very volatile
Common Stock Shares Outstanding24 M22.9 M6.4 M
Slightly volatile
Liabilities And Stockholders Equity152.1 M189.7 M116.5 M
Slightly volatile
Non Current Liabilities Total29.3 M21.5 M43.1 M
Slightly volatile
Other Current Assets4.6 MM3.1 M
Slightly volatile
Total Liabilities42.5 M34.6 M58.3 M
Slightly volatile
Preferred Stock Total Equity94.4 M142.8 M96.8 M
Slightly volatile
Total Current Assets135.9 M149.2 M104.7 M
Slightly volatile
Common Stock17.1 K18 K4.2 M
Very volatile
Property Plant And Equipment Net40 M38.1 M12.6 M
Slightly volatile
Non Current Assets Total42.5 M40.5 M13.7 M
Slightly volatile
Non Currrent Assets Other1.9 M1.8 M726.4 K
Slightly volatile
Other Assets1.091.15746.3 K
Pretty Stable
Deferred Long Term Liabilities3.8 M3.6 M1.8 M
Slightly volatile
Property Plant And Equipment Gross55.4 M52.8 M16.7 M
Slightly volatile
Property Plant Equipment9.1 M11.1 M5.6 M
Slightly volatile
Net Working Capital139.8 M132.5 M98.6 M
Slightly volatile
Short and Long Term Debt Total31.7 M30.2 M8.8 M
Slightly volatile
Other Liabilities82.1 K86.4 K2.1 M
Very volatile
Current Deferred Revenue9.9 M9.3 M8.6 M
Slightly volatile
Long Term Debt Total636.8 K659.7 K793.3 K
Slightly volatile
Capital Surpluse597.6 M890.6 M473.3 M
Slightly volatile
Capital Lease Obligations31.7 M30.2 M8.8 M
Slightly volatile
Capital Stock17.1 K18 K39.8 K
Very volatile
Short Term Debt3.1 M2.7 M1.5 M
Slightly volatile
Inventory4.8 M5.4 M5.9 M
Slightly volatile

Solid Biosciences Income Statement

Current ValueLast YearHistorical Average 10 Year Trend
Interest Income8.5 M8.1 M1.9 M
Slightly volatile
Selling General Administrative20.8 M31.9 M14.7 M
Slightly volatile
Other Operating Expenses81.4 M120 M56.3 M
Slightly volatile
Research Development60.6 M88 M41.6 M
Slightly volatile
Total Operating Expenses81.4 M120 M56.3 M
Slightly volatile
Net Interest Income8.5 M8.1 MM
Slightly volatile
Depreciation And Amortization2.3 MM1.4 M
Slightly volatile
Reconciled Depreciation2.7 M3.3 M1.6 M
Slightly volatile
Non Operating Income Net Other24.7 M23.5 M6.9 M
Slightly volatile
Non RecurringM8.3 M3.5 M
Slightly volatile
Selling And Marketing Expenses2.1 M2.3 M2.5 M
Slightly volatile

Solid Biosciences Cash Flow Statement

Current ValueLast YearHistorical Average 10 Year Trend
Sale Purchase Of Stock69.6 M83.5 M47.9 M
Slightly volatile
Stock Based Compensation8.3 M8.8 M5.5 M
Slightly volatile
Begin Period Cash Flow187.6 M178.7 M68.6 M
Slightly volatile
Depreciation2.1 MM1.4 M
Slightly volatile
Capital Expenditures2.7 M1.7 M1.8 M
Slightly volatile
Total Cash From Financing Activities3.4 M3.6 M58 M
Very volatile
End Period Cash Flow92.8 M85.1 M67.5 M
Slightly volatile
Issuance Of Capital Stock79.7 M67.6 M113.4 M
Slightly volatile

Financial Ratios

Current ValueLast YearHistorical Average 10 Year Trend
Price To Sales Ratio10.666.5112.0694
Slightly volatile
Days Sales Outstanding2.362.652.8925
Slightly volatile
Stock Based Compensation To Revenue1.061.070.9859
Pretty Stable
Capex To Depreciation0.640.683.1864
Slightly volatile
Inventory Turnover7.828.799.5829
Slightly volatile
Days Of Inventory On Hand29.933.6436.6759
Slightly volatile
Payables Turnover1.731.141.2677
Slightly volatile
Sales General And Administrative To Revenue2.223.222.2813
Slightly volatile
Research And Ddevelopement To Revenue5.68.725.3406
Slightly volatile
Capex To Revenue0.180.340.1496
Slightly volatile
Cash Per Share6.797.1532.8861
Slightly volatile
Days Payables Outstanding314330K
Slightly volatile
Income Quality0.70.880.787
Slightly volatile
Current Ratio6.188.046.9279
Slightly volatile
Receivables Turnover99.06111121
Slightly volatile
Graham Number28.7230.2393.7393
Pretty Stable
Debt To Equity0.20.190.059
Slightly volatile
Capex Per Share0.08320.08760.5863
Very volatile
Revenue Per Share1.571.091.7202
Slightly volatile
Interest Debt Per Share1.271.190.9833
Slightly volatile
Debt To Assets0.150.140.0458
Slightly volatile
Operating Cycle32.2636.2939.5684
Slightly volatile
Days Of Payables Outstanding314330K
Slightly volatile
Ebt Per Ebit1.060.92040.9879
Pretty Stable
Long Term Debt To Capitalization0.10.09840.0352
Slightly volatile
Total Debt To Capitalization0.160.150.0502
Slightly volatile
Debt Equity Ratio0.20.190.059
Slightly volatile
Quick Ratio6.148.046.9095
Slightly volatile
Net Income Per E B T1.030.880.9409
Pretty Stable
Cash Ratio3.754.593.8032
Slightly volatile
Days Of Inventory Outstanding29.933.6436.6759
Slightly volatile
Days Of Sales Outstanding2.362.652.8925
Slightly volatile
Free Cash Flow Operating Cash Flow Ratio1.141.171.046
Slightly volatile
Fixed Asset Turnover0.230.241.399
Slightly volatile
Debt Ratio0.150.140.0458
Slightly volatile
Price Sales Ratio10.666.5112.0694
Slightly volatile
Asset Turnover0.04940.03580.0532
Slightly volatile

Solid Biosciences Valuation Data

Current ValueLast YearHistorical Average 10 Year Trend
Market Cap50 M52.7 M324.7 M
Slightly volatile

Solid Fundamental Market Drivers

Cash And Short Term Investments123.6 M

Solid Upcoming Events

28th of March 2024
Upcoming Quarterly Report
View
9th of May 2024
Next Financial Report
View
31st of December 2023
Next Fiscal Quarter End
View
28th of March 2024
Next Fiscal Year End
View
30th of September 2023
Last Quarter Report
View
31st of December 2022
Last Financial Announcement
View

About Solid Biosciences Financial Statements

Solid Biosciences stakeholders use historical fundamental indicators, such as Solid Biosciences' revenue or net income, to determine how well the company is positioned to perform in the future. Although Solid Biosciences investors may analyze each financial statement separately, they are all interrelated. For example, changes in Solid Biosciences' assets and liabilities are reflected in the revenues and expenses on Solid Biosciences' income statement, which ultimately affect the company's gains or losses. Understanding these patterns can help in making the right long-term investment decisions in Solid Biosciences LLC. Please read more on our technical analysis and fundamental analysis pages.
Last ReportedProjected for Next Year
Current Deferred Revenue9.3 M9.9 M
Cost Of Revenue88 M92.4 M
Stock Based Compensation To Revenue 1.07  1.06 
Sales General And Administrative To Revenue 3.22  2.22 
Research And Ddevelopement To Revenue 8.72  5.60 
Capex To Revenue 0.34  0.18 
Revenue Per Share 1.09  1.57 
Ebit Per Revenue(15.12)(15.88)

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.
When determining whether Solid Biosciences LLC offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Solid Biosciences' financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Solid Biosciences Llc Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Solid Biosciences Llc Stock:
Check out the analysis of Solid Biosciences Correlation against competitors.
You can also try the Bonds Directory module to find actively traded corporate debentures issued by US companies.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Solid Biosciences. If investors know Solid will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Solid Biosciences listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share
(3.04)
Quarterly Revenue Growth
(1.00)
Return On Assets
(0.35)
Return On Equity
(0.66)
The market value of Solid Biosciences LLC is measured differently than its book value, which is the value of Solid that is recorded on the company's balance sheet. Investors also form their own opinion of Solid Biosciences' value that differs from its market value or its book value, called intrinsic value, which is Solid Biosciences' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Solid Biosciences' market value can be influenced by many factors that don't directly affect Solid Biosciences' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Solid Biosciences' value and its price as these two are different measures arrived at by different means. Investors typically determine if Solid Biosciences is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Solid Biosciences' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.